Join
Live feed
·
PRReleasevia Quantisnow
BioXcel Therapeutics Inc. logo

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

ByQuantisnow·Wall Street's wire, on your screen.
BTAI· BioXcel Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BTAI (BioXcel Therapeutics Inc.) and more on Quantisnow.